Benzinga | May 20, 2021 08:04AM EDT

Chiasma Highlights Presentation Of New Data From MPOWERED Phase 3 Trial At Upcoming European Congress of Endocrinology, Annual American Association of Clinical Endocrinology Meetings May 24-27

-- New clinical data accepted for oral and e-Poster presentation at AACE --

-- e-ECE clinical data previously presented at Endocrine Society's 2021 annual meeting --

NEEDHAM, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), ("Chiasma" or the "Company"), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, today announced that it will virtually present encore data from its MPOWERED(tm) Phase 3 clinical trial at the 23rd European Congress of Endocrinology (e-ECE) (May 22-26, 2021) and new data from the MPOWERED trial at the 30th Annual American Association of Clinical Endocrinology (AACE) Meeting (May 26-29, 2021).

Oral presentations and posters for display are summarized below:

e-ECE 2021 Oral Presentation

Title A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands

Presenter: Maria Fleseriu, M.D., FACE, Professor, Medicine and Neurological Surgery, Director OHSU Northwest Pituitary Center

Session Date/Time: Wednesday, May 26, 2021, 8:30 a.m. -- 9:30 a.m. EDT

e-ECE 2021 e-Poster Presentations

Title Safety Results from MPOWERED, a Phase 3 Trial of Oral Octreotide Capsules in Adults with Acromegaly

Presenter: Pamela Freda, M.D., Columbia University

Session Date/Time: Monday, May 24, 2021, 8:00 a.m. -- 8:30 a.m. EDT

Title Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands--Results from the MPOWERED Trial

Presenter: Nienke Biermasz, M.D., Ph.D., Leiden University Medical Center

Session Date/Time: Tuesday, May 25, 2021, 8:00 a.m. -- 8:30 a.m. EDT

Title: Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients with Acromegaly Who Are Inadequately Controlled with Monotherapy

Presenter: Maria Fleseriu, M.D., FACE, Professor, Medicine and Neurological Surgery, Director OHSU Northwest Pituitary Center

Session Date/Time: Tuesday, May 25, 2021, 8:00 a.m. -- 8:30 a.m. EDT

Title Improved Acromegaly Patient Satisfaction with Oral Octreotide Capsules Compared with Injectable Somatostatin Receptor Ligands in the MPOWERED Trial

Presenter: Murray B. Gordon, M.D., Allegheny General Hospital

Session Date/Time: Wednesday, May 26, 2021, 8:00 a.m. -- 8:30 a.m. EDT

AACE 2021 Oral Presentation

Title: Improved Quality of Life and Work Productivity in Patients with Acromegaly Receiving Oral Octreotide Capsules in the Phase 3 MPOWERED Trial

Presenter: Nienke Biermasz, M.D., Ph.D., Leiden University Medical Center

Session Date/Time: Thursday, May 27, 2021, 1:30 p.m. -- 1:45 p.m. EDT

AACE 2021 Late-Breaker e-Posters - Available online via the virtual e-Poster Gallery beginning May 26

Title: Effects of Prior Injectable Somatostatin Receptor Ligand Type and Dose in Patients with Acromegaly Receiving Oral Octreotide Capsules in the Phase 3 MPOWERED Trial

Lead Author: Murray B. Gordon, M.D., Allegheny General Hospital

Title: Injection Site Reactions and Their Impact in Patients with Acromegaly Receiving Injectable Somatostatin Receptor Ligands in the Phase 3 MPOWERED Trial

Lead Author: Murray B. Gordon, M.D., Allegheny General Hospital

To register and view the full schedules as well as abstracts, visit e-ECE's website here and AACE's website here.

Chiasma will sponsor a product theatre presentation at the AACE annual meeting titled "Understanding the Management of Acromegaly with MYCAPSSA(r) (octreotide) Delayed-Release Oral Capsules" on Wednesday, May 26 at 2:45 p.m. EDT. Anthony P. Heaney, M.D., Ph.D., Professor, UCLA, will lead the presentation and a live Q&A session.